HROW Harrow, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 10, 2026HROW Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
HROW Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 8 Feb. 2013 | 1-for-5 | Terbalik |
| 24 Feb. 2012 | 1-for-8 | Terbalik |
Tentang Harrow, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | HROW | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -31.4rata-rata 5T ≈-115.6 | ≈-115.6 | · | · | |
| P/S (TTM) | 4.1rata-rata 5T ≈4.8 | ≈4.8 | · | · | |
| P/B (MRQ) | 75.2rata-rata 5T ≈18.8 | ≈18.8 | 3.2 | Terlalu mahal | |
| Harga / FCF (TTM) | 227.8rata-rata 5T ≈-53.3 | ≈-53.3 | · | · | |
| Harga / Arus Kas (TTM) | 182.7rata-rata 5T ≈79.0 | ≈79.0 | · | · | |
| Harga / Nilai Buku Berwujud (MRQ) | -7.1 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | HROW | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Kotor (TTM) | 73.3%rata-rata 5T ≈73.2% | ≈73.2% | · | · | |
| Margin Operasi (TTM) | -1.00%rata-rata 5T ≈4.1% | ≈4.1% | 2.2% | Lemah | |
| EBITDA Margin (Margin EBITDA) | 11.7%rata-rata 5T ≈5.2% | ≈5.2% | 2.4% | Lemah | |
| Margin Sebelum Pajak (TTM) | -12.1%rata-rata 5T ≈-13.6% | ≈-13.6% | 9.0% | Lemah | |
| Margin Laba Bersih (TTM) | -13.5%rata-rata 5T ≈-14.0% | ≈-14.0% | 4.5% | Lemah | |
| ROA (TTM) | -9.8%rata-rata 5T ≈-10.2% | ≈-10.2% | -0.40% | Di bawah rata-rata | |
| ROE (TTM) | -114.8%rata-rata 5T ≈-49.8% | ≈-49.8% | -3.7% | Di bawah rata-rata | |
| ROIC | 218.6%rata-rata 5T ≈50.7% | ≈50.7% | 7.9% | Tingkat teratas |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | HROW | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 2.2rata-rata 5T ≈3.9 | ≈3.9 | 4.0 | Likuiditas rendah | |
| Quick Ratio (Rasio Cepat) | 1.9rata-rata 5T ≈2.3 | ≈2.3 | 2.6 | Di bawah rata-rata |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | HROW | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 36.4%rata-rata 5T ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 45.4%rata-rata 5T ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 41.0% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | HROW | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.7rata-rata 5T ≈0.7 | ≈0.7 | 0.7 | Tingkat teratas | |
| Inventory Turnover (Perputaran Persediaan) | 5.6rata-rata 5T ≈4.8 | ≈4.8 | 2.1 | Tingkat teratas | |
| Receivables Turnover (Perputaran Piutang) | 2.4rata-rata 5T ≈9.6 | ≈9.6 | 5.1 | Lemah | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$730.0K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 11, 2026 | $-0.46 | $-0.18 | -150.5% |
| 31 Maret 2026 | Mei 7, 2026 | $-0.74 | $-0.41 | -80.7% |
| 31 Des. 2025 | $0.17 | $0.38 | -54.8% | |
| 30 Sep. 2025 | $0.22 | $0.27 | -18.1% | |
| 30 Juni 2025 | $0.13 | $0.01 | — | |
| 31 Maret 2025 | $-0.50 | $-0.05 | -970.7% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.41 | $1.96 | $2.01 | $0.92 | $0.42 | $1.06 | $1.09 | $1.02 | $0.13 | $0.35 | $-0.14 | $0.88 | |
| Revenue / Share | $7.41 | $5.60 | $3.99 | · | · | $1.89 | $1.93 | $1.74 | · | · | · | · | |
| Cash Flow / Share | $1.19 | $-0.62 | $0.12 | · | · | $-0.04 | $0.04 | $0.03 | · | · | · | · | |
| Cash / Share | $1.96 | $1.33 | $2.11 | · | $1.57 | $0.16 | · | · | $0.19 | $0.48 | $0.28 | $0.89 | |
| EPS (TTM) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | · | 37,145,440 | 36,790,306 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | · | 38,875,005 | 38,853,855 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $0.77 | · | $1.27 | $1.35 | $1.58 | · | $1.63 | $1.65 | $1.71 | · | $2.16 | $0.74 | $0.73 | · | $0.04 | |
| Revenue / Share | $1.89 | $1.19 | · | $1.84 | $1.64 | $1.34 | · | $1.38 | $1.37 | $0.98 | · | $1.00 | $1.10 | $0.86 | · | · | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $0.55 | · | · | · | $-0.13 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $2.24 | $2.54 | · | $2.01 | $1.44 | $1.87 | · | $2.04 | $2.00 | $1.94 | · | $1.87 | · | · | · | $1.66 | |
| EPS (TTM) | $-0.97 | $-0.38 | · | $-0.15 | $-0.30 | $-0.61 | · | $-0.94 | $-0.95 | $-0.91 | · | $-0.44 | $-0.55 | $-0.64 | · | · |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $276M | $269M | · | $250M | $228M | $213M | · | $169M | $154M | $139M | · | $114M | $103M | $93M | · | $88M | |
| Net Income TTM | $-37M | $-15M | · | $-5M | $-10M | $-22M | · | $-33M | $-34M | $-31M | · | $-14M | $-16M | $-18M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -43.8 | -92.8 | · | -321.2 | -101.8 | -43.6 | · | -47.8 | -22.0 | -14.5 | · | -32.7 | -34.6 | -33.1 | · | · | |
| P/S | 5.8 | 4.9 | · | 7.1 | 4.9 | 4.5 | · | 9.5 | 4.8 | 3.4 | · | 4.4 | 5.6 | 6.9 | · | 3.7 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| EV / Revenue | · | · | · | 7.8 | 5.5 | 4.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.3% | -1.1% | · | -0.31% | -0.98% | -2.3% | · | -2.1% | -4.5% | -6.9% | · | -3.1% | -2.9% | -3.0% | · | · |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $272M | $200M | $130M | $89M | $72M |
| Margin Kotor % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Margin Operasi % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Laba Bersih | $-5M | $-17M | $-24M | $-14M | $-18M |
| EPS Dilusian | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Rasio Cepat | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $43M | $-24M | $2M | $-892.0K | $3M |
Pemilik institusional (13F) 242 pengaju · $1.1B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 41 (-6 vs Kuartal sebelumnya) | 34 (+4 vs Kuartal sebelumnya) | 80 (+11 vs Kuartal sebelumnya) | 69 (-9 vs Kuartal sebelumnya) | -305K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BlackRock, Inc. | $116.372.768 | 2.740.117 | 10,90% | Saham |
| Opaleye Management Inc. | $101.928.000 | 2.400.000 | 9,55% | Saham |
| VANGUARD GROUP INC | $94.162.467 | 1.921.683 | 8,82% | Saham |
| Private Capital Management, LLC | $67.899.762 | 1.598.770 | 6,36% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.188.994 | 1.417.212 | 5,64% | Saham |
| Deep Track Capital, LP | $41.153.430 | 969.000 | 3,86% | Saham |
| STATE STREET CORP | $39.917.043 | 939.888 | 3,74% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $38.466.487 | 905.560 | 3,60% | Saham |
| BAMCO INC /NY/ | $34.373.094 | 809.350 | 3,22% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.550.963 | 742.900 | 2,96% | Opsi beli |
| DIMENSIONAL FUND ADVISORS LP | $28.325.286 | 667.036 | 2,65% | Saham |
| Divisadero Street Capital Management, LP | $18.650.913 | 439.155 | 1,75% | Saham |
| CITADEL ADVISORS LLC | $16.622.758 | 391.400 | 1,56% | Opsi beli |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.459.036 | 387.545 | 1,54% | Saham |
| MARSHALL WACE, LLP | $15.689.905 | 369.435 | 1,47% | Saham |
| CITADEL ADVISORS LLC | $15.283.849 | 359.874 | 1,43% | Saham |
| NORTHERN TRUST CORP | $13.726.559 | 323.206 | 1,29% | Saham |
| Schonfeld Strategic Advisors LLC | $13.574.473 | 319.625 | 1,27% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.531.367 | 318.610 | 1,27% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.623.869 | 273.696 | 1,09% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $9.998.202 | 235.418 | 0,94% | Saham |
| CITADEL ADVISORS LLC | $9.895.510 | 233.000 | 0,93% | Opsi jual |
| Westside Investment Management, Inc. | $9.515.477 | 224.051 | 0,89% | Saham |
| FirstWave Capital Management LLC | $9.002.833 | 211.981 | 0,84% | Saham |
| Blackhawk Capital Partners, LLC | $8.631.645 | 203.241 | 0,81% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.074.227 | 190.116 | 0,76% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.827.221 | 184.300 | 0,73% | Opsi jual |
| JANE STREET GROUP, LLC | $7.772.010 | 183.000 | 0,73% | Opsi beli |
| STIFEL FINANCIAL CORP | $7.682.532 | 180.893 | 0,72% | Saham |
| GOLDMAN SACHS GROUP INC | $6.573.380 | 154.777 | 0,62% | Saham |
| ROYCE & ASSOCIATES LP | $6.565.310 | 154.587 | 0,62% | Saham |
| Crawford Fund Management, LLC | $6.035.836 | 142.120 | 0,57% | Saham |
| Ikarian Capital, LLC | $5.766.364 | 135.775 | 0,54% | Saham |
| Advantage Alpha Capital Partners LP | $5.374.624 | 111.553 | 0,50% | Saham |
| MORGAN STANLEY | $5.105.094 | 120.204 | 0,48% | Saham |
| Diametric Capital, LP | $4.965.082 | 116.908 | 0,47% | Saham |
| WOODMONT INVESTMENT COUNSEL LLC | $4.748.571 | 111.810 | 0,44% | Saham |
| BANK OF AMERICA CORP /DE/ | $4.565.398 | 107.497 | 0,43% | Saham |
| FIRST TRUST ADVISORS LP | $4.260.378 | 100.315 | 0,40% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.146.219 | 97.627 | 0,39% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $3.934.590 | 92.644 | 0,37% | Saham |
| 12th Street Asset Management Company, LLC | $3.882.140 | 91.409 | 0,36% | Saham |
| Lumbard & Kellner, LLC | $3.835.975 | 90.322 | 0,36% | Saham |
| Steward Partners Investment Advisory, LLC | $3.832.960 | 90.251 | 0,36% | Saham |
| Bank of New York Mellon Corp | $3.625.366 | 85.363 | 0,34% | Saham |
| MILLENNIUM MANAGEMENT LLC | $3.575.210 | 84.182 | 0,33% | Saham |
| EQUITABLE TRUST CO | $3.371.184 | 79.378 | 0,32% | Saham |
| Squarepoint Ops LLC | $3.126.726 | 73.622 | 0,29% | Saham |
| DEUTSCHE BANK AG\ | $3.009.509 | 70.862 | 0,28% | Saham |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.004.668 | 70.748 | 0,28% | Saham |
Aktivis & pemilik 5%+ 5 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Mark L. Baum ×3 pengajuan | 7 April 2025 | 10,69% | Amandemen | · | SEC |
| 27 April 2021 | · | Pengajuan awal | · | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 pengajuan | 30 Agu 2016 | · | Pengajuan awal | Investasi pasif | SEC |
| Dr. Robert J. Kammer ×2 pengajuan | 16 Agu 2013 | · | Pengajuan awal | · | SEC |
| DermaStar International, LLC ×7 pengajuan | 10 Agu 2012 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 32 orang dalam · 10 pejabat · 17 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER | 14 Mei 2026 P | 2.996.130 | 1 | 0 | $302.000 |
| John P. Saharek | CEO & President, ImprimisRx | 3 April 2025 M | 467.388 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 Juni 2009 A | 1.954.125 | 0 | 0 | $0 |
| Andrew Boll | PRESIDENT AND CFO | 14 Mei 2026 P | 814.679 | 1 | 0 | $104.650 |
| Clayton D Edwards | Chief Operating Officer | 13 April 2017 A | · | 0 | 0 | $0 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 14 Agu 2026 M | 0 | 0 | 1 | $-450.000 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 Jan. 2026 A | · | 0 | 0 | $0 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 1 Sep. 2025 A | · | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1 April 2013 A | · | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 Feb. 2010 A | · | 0 | 0 | $0 |
| Perry J. Sternberg | Direktur | 18 Juni 2026 A | · | 0 | 0 | $0 |
| Adrienne L Graves | Direktur | 18 Juni 2026 A | 1.000 | 1 | 0 | $31.070 |
| Lauren P Silvernail | Direktur | 18 Juni 2026 A | 1.000 | 1 | 0 | $31.000 |
| Martin A. Makary | Direktur | 14 Juni 2024 A | 45.000 | 0 | 0 | $0 |
| Teresa Sparks | Direktur | 21 Juni 2023 A | · | 0 | 0 | $0 |
| Lawrence R. Van Horn | Direktur | 21 Juni 2023 A | 1.860 | 0 | 0 | $0 |
| Richard L Lindstrom MD | Direktur | 30 Sep. 2022 S | 26.100 | 0 | 0 | $0 |
| Robert J Kammer | Direktur | 25 Juni 2021 A | 797.327 | 0 | 0 | $0 |
| Anthony Principi | Direktur | 28 Sep. 2020 M | 93.798 | 0 | 0 | $0 |
| Stephen G Austin | Direktur | 16 Maret 2020 M | 91.987 | 0 | 0 | $0 |
| William H. Nelson | Direktur | 10 Juni 2016 A | 12.904 | 0 | 0 | $0 |
| August Shelby Bassani | Direktur | 4 Sep. 2014 A | 13.488 | 0 | 0 | $0 |
| Peter C Kenny | Direktur | 2 Okt. 2013 A | 8.947 | 0 | 0 | $0 |
| Paul Finnegan | Direktur | 27 Juni 2013 A | 6.865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Direktur | 27 Juni 2013 A | 45.927 | 0 | 0 | $0 |
| Opaleye Management Inc. | Pemilik 10% | 4 Maret 2026 S | 59.428 | 0 | 6 | $-9.183.890 |
| Donald Paul Miloni | Pemilik 10% | 19 Mei 2015 S | 468.576 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Pemilik 10% | 12 Juli 2012 J | 0 | 0 | 0 | $0 |
| John N Bonfiglio | · | 20 Okt. 2010 A | 50.000 | 0 | 0 | $0 |
| John T Lomoro | · | 19 Juni 2009 A | · | 0 | 0 | $0 |
| Lynn C Swann | · | 21 Nov. 2008 A | 25.000 | 0 | 0 | $0 |
| Anthony S Thornley | · | 21 Nov. 2008 A | 60.900 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 32 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,23% | 6.543 NS | 31 Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,28% | 110.031 SH | 11 Sep. 2026 | Harian |
| IHE · iShares Trust | 0,28% | 122.556 SH | 11 Sep. 2026 | Harian |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,25% | 82.646 NS | 31 Juli 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 41.081 NS | 31 Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34.722 SH | 19 Agu 2026 | Harian |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 50.393 NS | 31 Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,08% | 302.749 SH | 11 Sep. 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 2.662 SH | 2 Okt. 2026 | Harian |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 7.488 NS | 31 Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 7.406 NS | 31 Juli 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 15.475 NS | 31 Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186.298 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,04% | 826.648 SH | 11 Sep. 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2.979 SH | 2 Okt. 2026 | Harian |
| ISCG · iShares Trust | 0,03% | 8.739 SH | 11 Sep. 2026 | Harian |
| DFAS · Dimensional ETF Trust | 0,03% | 125.599 NS | 31 Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383.679 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,02% | 94.953 SH | 19 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 15.109 NS | 31 Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.287 SH | 11 Sep. 2026 | Harian |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 31 Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 61.585 NS | 31 Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10.408 NS | 31 Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 2.739 NS | 31 Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11.363 NS | 31 Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45.401 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 7.042 SH | 4 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.001.445 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.637 SH | 19 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 1.222 SH | 11 Sep. 2026 | Harian |
| SMLF · iShares Trust | · | 34.093 SH | 11 Sep. 2026 | Harian |
HROW Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
9 analis · 2026-09-29Target rata-rata $65.00 +113,3%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| SPTX | · | · | · | · | · | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.